{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:38:24Z","timestamp":1760852304928},"reference-count":30,"publisher":"Wiley","issue":"s386","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":4527,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1995,4]]},"abstract":"<jats:p>The clinically tested reversiblc inhibitors of monoamine oxidase A (RIMAs) include brofaromine, moclobemide and toloxatone. Moclobemide has shown unequivocal antidepressant activity against serious deprcssivc illness in 4 placebo\u2010controlled double\u2010blind trials. It has been compared with amitriptyline, imipramine, clomipramine, desipramine, maprotiline, fluoxetine, fluvoxamine, tranylcypromine. toloxatone, mianserin and amineptine in the treatment of depressive disorders. Meta\u2010analysis showed convincing evidence of moclobemide efficacy, comparable with the most potent antidepressants available. The efficacy of moclobemide has been demonstrated in psychotic and non\u2010psychotic depression, in depression with and without melancholia, in endogenous depression (both unipolar and bipolar), in retarded depression and in agitated depression. The efficacy of moelobemide, allied to the unusually benign side effect profile, has led to exploration of its use in other disorders. Two small studies have given encouraging results in the treatment of attention\u2010deficit hyperactivity disorder. Large placebo\u2010controlled studies have shown the activity of moclobemide in the depression that accompanies dementia (such as senile dementia of Alzheimer type). The results also suggested that, in this patient population, cognitive ability improved in parallel. Social phobia has also been shown to improve on treatment with either moclobemide or brofaromine. Clinical trials are in progress on the effect of moclobemide in chronic fatigue syndrome. Moreover, there are encouraging results with the use of brofaromine and moclobemide in panic disorder. Other disorders in which treatment with RIMA is of interest include agoraphobia, bulimia, borderline personality disorder, post\u2010traumatic stress disorder, compulsive hair pulling (trichotillomania), dysmorphophobia, kleptomania as well as various anxiety syndromes.<\/jats:p>","DOI":"10.1111\/j.1600-0447.1995.tb05923.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T13:24:28Z","timestamp":1187875468000},"page":"40-43","source":"Crossref","is-referenced-by-count":31,"title":["Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders"],"prefix":"10.1111","volume":"91","author":[{"given":"R. G.","family":"Priest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Gimbrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Steinert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"issue":"6","key":"e_1_2_1_2_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1192\/S0007125000297493","article-title":"Biochemical aspects of the pharmacology of moclobemide: The implications of animal studies","volume":"155","author":"Callingham BA","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"6","key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000297420","article-title":"Antidepressants of the future","volume":"155","author":"Priest RG","year":"1989","journal-title":"Br J Psychiatry"},{"issue":"6","key":"e_1_2_1_4_2","first-page":"1","article-title":"Depression and reversible monoamine oxidase inhibitors \u2010 new perspectives","volume":"155","year":"1989","journal-title":"Br J Psychiatry"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb05322.x"},{"issue":"360","key":"e_1_2_1_6_2","first-page":"35","article-title":"The treatment of depression in the 1990 s\u2010a focus on moclobemide","volume":"82","year":"1990","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246260"},{"key":"e_1_2_1_8_2","first-page":"1","article-title":"Recent advances in antidepressant drugs","volume":"82","author":"Priest RG","year":"1992","journal-title":"S Afr Med J"},{"key":"e_1_2_1_9_2","first-page":"Sl","article-title":"RIMA: a new concept in the treatment of depression","volume":"106","year":"1992","journal-title":"Psychopharmacology"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb05323.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1017421"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246248"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1192\/S0007125000297523"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246250"},{"issue":"2","key":"e_1_2_1_15_2","first-page":"555","article-title":"Efficacy of moclobemide in different patient groups","volume":"16","author":"Angst J","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_16_2","unstructured":"HetzelW Sch\u00e4ublin\u2010LoidlM StablM.Moclobemide: safety update on adverse events and vital signs. Roche Research Report data on file."},{"issue":"6","key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/S0007125000297481","article-title":"Antidepressants in panic disorders","volume":"155","author":"Liebowitz MR","year":"1989","journal-title":"Br J Psychiatry"},{"key":"e_1_2_1_18_2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1987"},{"key":"e_1_2_1_19_2","unstructured":"BakishD SaxenaBM BowenR D'SouzaJ.Reversible monoamine oxidase (MAO\u2010A) inhibitors in panic disorder. Submitted."},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-1014418"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246258"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.126.6.884"},{"key":"e_1_2_1_23_2","unstructured":"BailadorP DelfinoA.Moclobemide in attention deficit disorder with hyperactivity: results of a double\u2010blind comparison with placebo in children. Abstracts of 9th Congress of the European Society of Child and Adolescent Psychiatry \u2010 ESCAP London:September 1991."},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02246259"},{"key":"e_1_2_1_25_2","unstructured":"AmreinR BischoffR BullerC MontanariN NeumannN StablM.Does moclobemide exert specific effects on cognitive functions? Roche Research Report data on file."},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1990.tb05321.x"},{"key":"e_1_2_1_27_2","article-title":"Reversible MAO\u2010A inhibitors in social phobia","author":"Liebowitz MR","journal-title":"Clin Neuropharmacol"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.49.4.290"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810340070009"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.161.3.353"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0924-977X(92)90032-4"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1995.tb05923.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1995.tb05923.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:38:32Z","timestamp":1695764312000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1995.tb05923.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,4]]},"references-count":30,"journal-issue":{"issue":"s386","published-print":{"date-parts":[[1995,4]]}},"alternative-id":["10.1111\/j.1600-0447.1995.tb05923.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1995.tb05923.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,4]]}}}